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Available online 30 July 2016A wide variety of clinical syndromes has been associated with antibodies to voltage-gated potassium channels
(VGKCs). Six years ago, it was discovered that patients do not truly have antibodies to potassium channels, but
to associated proteins. This enabled the distinction of three VGKC-positive subgroups: anti-LGI1 patients, anti-
Caspr2 patients and VGKC-positive patients lacking both antibodies. Patients with LGI1-antibodies have a limbic
encephalitis, oftenwith hyponatremia, and about half of the patients have typical faciobrachial dystonic seizures.
Caspr2-antibodies cause a more variable syndrome of peripheral or central nervous system symptoms, almost
exclusively affecting older males. Immunotherapy seems to be beneﬁcial in patients with antibodies to LGI1 or
Caspr2, stressing the need for early diagnosis. Half of the VGKC-positive patients lack antibodies to both LGI1
and Caspr2. This is a heterogeneous group of patients with a wide variety of clinical syndromes, raising the ques-
tion whether VGKC-positivity is truly a marker of disease in these patients. Data regarding this issue are limited,
but a recent study did not show any clinical relevance of VGKC-positivity in the absence of antibodies to LGI1 and
Caspr2. The three VGKC-positive subgroups are essentially different, therefore, the lumping term ‘VGKC-complex
antibodies’ should be abolished.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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In the last ten years several antibodies to neuronal surface antigens
have been identiﬁed. Most of these antibodies are proven or strongly
believed to be pathogenic and cause a well-deﬁned syndrome, such as
anti-NMDA-receptor encephalitis [1]. However, controversy exists
regarding antibodies to the voltage-gated potassium channel complex
(VGKC). VGKCs are present on the membrane of neurons in both
the central and peripheral nervous system. They play a crucial rolethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Antibody-mediated disturbance of this process was initially
suspected in patients with neuromyotonia, Morvan's syndrome and
limbic encephalitis [2–4]. Sera of these patients tested positive in
the VGKC-radioimmunoassay (RIA), a test measuring the amount of an-
tibody bound to solubilized complexes of VGKCs. However, all attempts
to show reactivity of these samples to cells transfected with intact
VGKCs failed. Subsequent investigations demonstrated that the anti-
bodies were not directed to the VGKC itself, but to associated proteins,
which are included in the VGKC-test. Two of these proteins were
identiﬁed in 2010: leucine-rich glioma-inactivated1 (LGI1) and
contactin-associated protein-like 2 (Caspr2) [5,6]. This major step
forward enabled the distinction of three VGKC-positive subgroups:
anti-LGI1 patients, anti-Caspr2 patients and VGKC-positive patients
lacking both antibodies. This review is structured accordingly, ﬁrst de-
scribing the clinical syndrome caused by LGI1-antibodies. These pa-
tients have a limbic encephalitis, often with hyponatremia, and about
half of the patients have typical faciobrachial dystonic seizures (FBDS).
Caspr2-antibodies cause amore variable syndromeof peripheral or cen-
tral nervous system symptoms, almost exclusively affecting older
males. The third section reviews the group of VGKC-positive patients
lacking antibodies to LGI1 and Caspr2. About half of the VGKC-positive
patients belong to this group (varying between 16% and 77% in the re-
spective studies) [5,7–11]. The group encompasses children and adults
with a wide variety of clinical syndromes, raising the question whether
VGKC-positivity is truly a marker for disease in these patients. A
recent study focused on this issue did not detect clinical relevance of
VGKC-positivity in the absence of LGI1 and Caspr2 antibodies [10].
(See Table 1.)
2. VGKC-positive subgroups
2.1. LGI1-antibodies
LGI1 is a secreted protein, mainly present in the hippocampus and
the temporal cortex. It is capable of binding to proteins of the ADAM
(a disintegrin andmetalloproteinase) family. LGI1 connects presynaptic
ADAM23 to postsynaptic ADAM22, which is essential for inhibitory
signal transmission from the presynaptic potassium channel to the
postsynaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic-acid
(AMPA)-receptor. Antibodies to LGI1 reduce LGI1-ADAM interaction
and reversibly reduce postsynaptic AMPA-receptor clusters [12]. A ge-
netic disruption of the LGI1 protein in humans causes autosomal-
dominant lateral temporal lobe epilepsy [13,14]. LGI1 knock-out mice
die of lethal epilepsy in the postnatal third week, conﬁrming the
essential role of LGI1 in synaptic transmission [15].
Approximately 250 anti-LGI1-encephalitis patients have been re-
ported so far. Major underdiagnosis of this relatively ‘new’ disease enti-
ty is suspected, as we have seen a serious increase in incidence over the
last few years (own observation). Median age of onset is around
60 years with a 2:1 male predominance [5,6,16]. The vast majority ofTable 1
Subgroups of VGKC-positive patients.
LGI1 positive Caspr2 positive
Patient characteristics 60–70% male 80–90% male
Age ~ 60 Age ~ 70
Clinical syndrome Limbic encephalitis (~50% FBDS) Peripheral nervo
Limbic encephali
Morvan's syndro
Hyponatremia 60% Rare
VGKC RIA result⁎ (range) N400 pM
(200–1500 pM)
N200 pM
(50–1000 pM)
Response to immunotherapy Good Good
CFS = cramp fasciculation syndrome. RIA = radioimmunoassay.
⁎ Cut-off value for positivity 100 pM.the patients have a limbic encephalitis, characterized by subacute
disturbance of memory, behavior and spatial orientation. Seizures are
common, and include both subtle partial seizures and (secondary) gen-
eralized tonic clonic seizures. Very speciﬁc for LGI1-encephalitis, but
only present in half of the patients, are faciobrachial dystonic seizures
(FBDS), also referred to as tonic seizures [17,18]. FBDS are very brief
(b3 s) unilateral contractions of the arm, often involving the ipsilateral
face (or leg), and occurring up to 100 times a day. Patients drop items
and falls are reported [18,19]. FBDS are often unrecognized by physi-
cians, and only the minority of the EEG recordings show ictal changes
[17,18]. FBDS often precede the onset of cognitive decline, and prompt
start of immunotherapy could possibly prevent progression to limbic
encephalitis [20]. Hyponatremia is present in 60% of the anti-LGI1 pa-
tients. Brain MRI shows T2 high signal of the medial temporal lobe in
two-thirds of the patients [5,6,16]. Basal ganglia abnormalities are
seen in some patients with FBDS [21]. CSF is usually unremarkable, or
cell count or protein are minimally raised. Tumor screening is positive
in 0–11% of the patients [5,6,16,22]. Various tumors seem to be asso-
ciated, but thymoma and lung cancer are probably most common.
LGI1-antibodies can be detected by a (commercially available) cell-
based assay, or by the typical staining pattern seen on immunohisto-
chemistry (Fig. 1). Antibodies can be found in both serum and CSF, but
to our experience, serum testing is more sensitive. The result (pM) of
the VGKC-RIA is usually increased to a plurality of the cut-off value for
positivity [22]. The effect of immunotherapy has not been studied in
randomized trials, but is favorable in smaller patient series. Most pa-
tients are treated with intravenous or oral corticosteroids, intravenous
immunoglobulin (IVIg) or a combination of both, and show substantial
improvement [5,6,16]. Seizures, especially FBDS, often disappear in-
stantly, while cognitive improvement is slow (own data). Data regard-
ing second line therapy are limited. In a series of ﬁve patients treated
with rituximab marked improvement was seen in only one patient.
This disappointing outcome might be due to the long delay until start
of rituximab (median 414 days) [23]. Relapse rate of anti-LGI1 enceph-
alitis ranges between 0–20%, but will probably increase with extended
follow up [6,16,22]. To our experience, relapses can occur more than
seven years after the initial disease episode. Long term outcome is
currently studied more extensively.
2.2. Caspr2-antibodies
Caspr2 is amembrane protein expressed in the central and peripher-
al nervous system. Its cytoplasmic domain is essential for potassium
channel clustering at the juxtaparanodes of myelinated axons [24].
Mutations in the gene encoding for Caspr2 (CNTNAP2) are associated
with focal epilepsy, schizophrenia and other disorders [25,26]. Antibod-
ies target multiple epitopes of the Caspr2 protein [27], and react to both
brain and peripheral nerve [28].
Less than hundred anti-Caspr2 patients have been reported so far,
with age of onset around sixty years. For unknown reasons, 80–90%
of the patients are male [5,28]. Common central nervous systemLGI1 and Caspr2 negative
50% male
All ages
us hyperexcitability
tis
me
Variable, including cognitive decline, psychiatric symptoms,
epilepsy, pain syndrome, CFS
Rare
b300 pM
(100–300 pM)
Limited data; most likely equal to matched
VGKC-negative patients
FC D
E
A B
0 0.25 0.5 0.75 1 mm
Fig. 1. Cell-based assay (A–B) and immunohistochemistry (on rat brain, C–F). (A) Caspr2-antibody positive sample. (B) Caspr2-antibody negative control. (C) LGI1-antibody positive
sample, showing staining of the hippocampus, except for the inner 1/3rd of the dentate gyrus (blue arrow). (D) Caspr2-antibody positive sample, showing diffuse staining of the
hippocampus. (E) Negative control sample. (F) VGKC-radioimmunoassay positive sample (titer 118 pM) without antibodies to LGI1 and Caspr2. The hippocampus shows no staining.
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reported as well [5,28,29]. Peripheral nervous hyperexcitability causes
fasciculations and cramps. A combination of these central and peripher-
al nervous system symptoms, accompanied by autonomic dysfunction
and insomnia, is known as Morvan's syndrome. Morvan's syndrome is
strongly associated with Caspr2-antibodies, but seronegative patients
are reported as well [30]. Other symptoms associated with Caspr2 anti-
bodies are pain andweight loss [5,28,31]. Caspr2-encephalitis potential-
ly mimics Creutzfeldt-Jakob disease (CJD) and some patients with a
positive Caspr2-antibody test ultimately appeared to have CJD [32,33].
It is unknown whether the anti-Caspr2 tests in these patients were
false positive, or that the antibodies were actually present but clinically
irrelevant. To our experience, a positive anti-Caspr2 cell-based assay
requires further laboratory conﬁrmation and physicians should be espe-
cially wary if the VGKC-RIA titer is not clearly raised (own observation).
Tumor incidence in anti-Caspr2 patients ranges from 0 to 32% [5,28,31].
Thymomas are most common and some of these patients suffer from
myasthenia gravis as well [30]. Several other tumors, such as lung
tumor and endometrial carcinoma have been reported [5,34,35].
Tumor treatment is essential for neurological improvement. In
addition, and in non-tumor patients, immunotherapy seems to be
beneﬁcial [5,28]. First line treatment consists of corticosteroids, IVIg or
plasma exchange, but no trials have compared different treatment
approaches. Prompt start of treatment is recommended, as early
treatment was associated with better outcome in NDMA-receptor en-
cephalitis [36]. To our experience, Caspr2-antibody mediated disease
can relapse, similar to syndromes caused by antibodies to LGI1 or
NMDA-receptors.2.3. VGKC-positivity in the absence of antibodies to LGI1 and Caspr2
The clinical spectrum of VGKC-positive patients has emerged, includ-
ing epilepsy, pain syndromes, cognitive decline, polyneuropathy and
cramp fasciculation syndromes [8,11,37]. This clinical heterogeneity
mostly concerns VGKC-positive patients lacking LGI1 and Caspr2 anti-
bodies. This raises the question whether these patients actually have a
common disease entity [8,22]. Data answering this question are limited,
partly because these patients can only be separated from patients with
LGI1 or Caspr2 antibodies since six years. Recent studies do include anti-
body subtyping, but unfortunately many studies subsequently lump the
three groups for analysis, or classify patients according to VGKC-RIA re-
sults instead of speciﬁc antibody results [7,8,38,39]. Higher VGKC-RIA re-
sults are linked to neuroinﬂammatory conditions, and to the detection of
LGI1-antibodies [7–9,31,40]. These associations are broadly supported,
but do not contribute to clinical reasoning in VGKC-positive patients
lacking LGI1 and Caspr2 antibodies. The majority of VGKC-positive pa-
tients, but especially those with LGI1 or Capsr2 antibodies, respond to
immunotherapy [11,37], suggesting an inﬂammatory condition in all.
However, therapeutic response is not compared to VGKC-negative con-
trols and could also be a reﬂection of the natural course of any disease.
A recent retrospective study analyzed the clinical relevance of VGKC-
positivity in the absence of LGI1 and Caspr2 antibodies. Twenty-ﬁve
VGKC-positive patients (LGI1/Caspr2 antibody negative)were compared
to ﬁfty VGKC-negative patients,matched for age, gender and clinical syn-
drome. The two groups were not different in evidence for autoimmune
inﬂammation (p = 0.38), according to predeﬁned criteria blindly
assessed by independent researchers. Patients with limbic encephalitis
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with other syndromes, irrespective of VGKC-RIA results. VGKC-positive
patients lacking antibodies to LGI1 and Caspr2 did not show better re-
sponse to immunotherapy than matched VGKC-negative patients. In
conclusion, VGKC-positivity in the absence of antibodies to LGI1 and
Caspr2 did not show to be a marker for autoimmune inﬂammation
[10]. However, novel antibodies might be detected in small subgroups
of VGKC-positive patients in the future, especially in those with limbic
encephalitis. More studies will hopefully add to this clinically relevant
topic, ﬁnally providing clarity after years of considerable misinterpreta-
tion of VGKC-results.
3. Conclusion
Three groups of VGKC-positive patients should be distinguished.
Patients with LGI1-antibodies suffer from limbic encephalitis with dif-
ferent seizure types and hyponatremia. Patients with Caspr2-antibodies
can have both central and peripheral nervous system symptoms,
accompanied by insomnia, weight loss and pain. Case series show sufﬁ-
cient evidence for beneﬁt of immunotherapy in both LGI1 and Caspr2
antibodymediated disease. Prompt diagnosis is essential, tumor screen-
ing is indicated, and both syndromes can relapse. A third group of
VGKC-positive patients lack antibodies to LGI1 and Caspr2. Data regard-
ing this group are limited. A recent study did not detect clinical
relevance of VGKC-positivity in the absence of LGI1 and Caspr2 antibod-
ies. Lumping the three VGKC-positive groups using the term ‘VGKC-
complex antibodies’ should be discouraged and abolished.
Take-home messages
• VGKC-positive patients should be classiﬁed according to the presence
(or absence) of antibodies to LGI1 and Caspr2
• LGI1-antibodies cause a limbic encephalitis, oftenwith hyponatremia.
• Caspr2-antibodies are mainly present in older male patients with
a limbic encephalitis, peripheral nervous hyperexcitability or a
combination of both.
• Antibodies to LGI1 or Caspr2 are assumed to be pathogenic and the
associated syndromes respond well to immunotherapy. A minority
of the patients have a tumor.
• A substantial part of the VGKC-positive patients lack antibodies to
LGI1 and Caspr2. A recent study did not show any clinical relevance
of VGKC-positivity in these patients.
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